Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04385160 · ClinicalTrials.gov registry record
Myeloproliferative Neoplasms (MPN) and COVID-19
A clinical trial, sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS.
- Completed
- Registry status
- 552
- Enrollment target
NCT04385160 is a clinical trial that has completed, run by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS. The registered enrollment target is 552 participants.
The verdict
NCT04385160 has completed, sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS.
- COMPLETED
- Registry status
- 552 participants
- Enrollment target
Study Summary
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2022-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04385160
The ClinicalTrials.gov registry entry for NCT04385160 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 552 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04385160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04385160 about?
NCT04385160 is a clinical study titled "Myeloproliferative Neoplasms (MPN) and COVID-19". An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential throm...
What is the current status of trial NCT04385160?
This trial is currently completed. The enrollment target is 552 participants. The study started on 2020-05-13. Estimated completion is 2022-08-31.
Who is sponsoring clinical trial NCT04385160?
This trial is sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.